Kringle Pharma Receives FDA Clearance of IND Application for Oremepermin Alfa in Acute Spinal Cord Injury
Filed with TSE · · 2 pages · English
Story so far
Earlier from Kringle Pharma
- Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury
- Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)
- Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury
- Update on the Investigator-initiated Phase 2 Study in Patients with ALS
- Kringle Pharma Files Patent Application for Treatment of Chronic Spinal Cord Injury
Follow Kringle Pharma into a list and get an email when it puts out news.
Follow Kringle Pharma